GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Globe Newswire•28/09/2026•08:40 ET
0
Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPF
LA JOLLA, CA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, Chief Executive Officer, and Vipin Kumar, Chief Scientific Officer, will deliver presentations at the 10th IPF Summit, taking place September 29 through October 1, 2026, in Boston, Massachusetts.
Get started
Create a free account to read the full story and Whiz Insights.